Keenova Therapeutics Expected To Slip To Loss From Cont Opns In Q4

Keenova Therapeutics reported unaudited Q4 results and issued FY2026 guidance of net sales between $1.94 billion and $2.00 billion and adjusted EBITDA around $730 million. This is a company-level forward outlook that is likely to produce a modest stock reaction pending audited results and any further detail on the EBITDA range.

Analysis

Keenova Therapeutics reported unaudited Q4 results and issued FY2026 guidance of net sales between $1.94 billion and $2.00 billion and adjusted EBITDA around $730 million. This is a company-level forward outlook that is likely to produce a modest stock reaction pending audited results and any further detail on the EBITDA range.